Source comparison
Tesamorelin + Ipamorelin Comparison
Mechanism of Action GHRH receptor agonist. Stimulates pituitary GH release directly Ghrelin receptor agonist. Amplifies GHRH and inhibits somatostatin Dual-pathway activation. GHRH + ghrelin receptors simultaneously Combined mechanism produces synergistic GH p
This comparison does not assign a generated winner or score.
- Mechanism of Action
- GHRH receptor agonist. Stimulates pituitary GH release directly
- Ghrelin receptor agonist. Amplifies GHRH and inhibits somatostatin
- Dual-pathway activation. GHRH + ghrelin receptors simultaneously
- Combined mechanism produces synergistic GH pulse amplitude 2–3× either compound alone (Cordido et al., 1995)
- Peak GH Elevation
- 15–25ng/mL at 2mg dose
- 18–28ng/mL at 200–300mcg dose
- 45–70ng/mL when dosed concurrently
- Synergistic effect confirmed across multiple trials. Not merely additive
- Visceral Fat Reduction
- 10–15% over 26 weeks (COSMOS trial)
- Minimal direct lipolytic effect. Works via GH elevation
- 15–20% over 12–16 weeks in research protocols
- Tesamorelin provides direct VAT targeting; ipamorelin amplifies the GH-mediated lipolysis
- Cortisol Impact
- No significant elevation
- No elevation (selective GHS-R1a agonism)
- No elevation in combination
- Critical advantage over GHRP-2 or GHRP-6, which raise cortisol 2–3× baseline
- Half-Life
- 26–38 minutes
- 2–3 hours
- Staggered clearance allows extended GH elevation window
- Ipamorelin's longer half-life sustains the pulse initiated by tesamorelin
- Typical Research Dose
- 1–2mg subcutaneous daily
- 200–300mcg subcutaneous 2–3× daily
- 1mg tesamorelin + 200mcg ipamorelin once daily, or split-dose protocol
- Split dosing (AM/PM) mimics natural pulsatile GH secretion more accurately
- The bottom line: tesamorelin + ipamorelin blend for men outperforms either peptide in isolation when the goal is visceral fat reduction with preserved lean mass. The synergy is mechanism-based, not marketing.